Braun J, Baraliakos X, Deodhar AA, et al. Secukinumab Demonstrates Low Radiographic Progression and Sustained Efficacy through 4 Years in Patients with Active Ankylosing Spondylitis. ACR 2017, abstract 3L.
Bimekizumab behaalt als eerste primair eindpunt ASAS40-respons na 12 weken
jun 2018 | Spondyloartritis